04:16 AM EST, 02/12/2025 (MT Newswires) -- MaxCyte ( MXCT ) said Wednesday it is licensing its cell-engineering technology to TG Therapeutics ( TGTX ) .

Financial terms were not disclosed.

Under the terms of the agreement, TG Therapeutics ( TGTX ) will gain non-exclusive research, clinical and commercial rights to use MaxCyte's ( MXCT ) Flow Electroporation technology and ExPERT platform. In return, MaxCyte ( MXCT ) will receive annual licensing fees and other revenue, the company said.